Liu T J, Kay M A, Darlington G J, Woo S L
Howard Hughes Medical Institute, Department of Cell Biology, Houston, Texas 77030.
Somat Cell Mol Genet. 1992 Jan;18(1):89-96. doi: 10.1007/BF01233451.
Phenylketonuria (PKU) is a metabolic disorder secondary to a deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH). The recent creation of a mouse strain for PAH deficiency has provided an excellent model system to explore the possibility of its phenotypic correction by hepatic gene therapy. A recombinant retrovirus containing the mouse PAH cDNA under the transcriptional control of the human CMV promoter was constructed and used to transduce hepatocytes isolated from PAH-deficient mice. Viral-transduced hepatocytes produced dramatically higher levels of mouse PAH mRNA as compared to control mock-infected hepatocytes. The PAH mRNA was translated efficiently into PAH protein that is capable of converting phenylalanine to tyrosine in vitro. These results demonstrate that the PAH-deficient mouse hepatocytes can be readily reconstituted by retroviral-mediated gene transduction, which is a crucial step towards somatic gene therapy for PKU.
苯丙酮尿症(PKU)是一种继发于肝脏酶苯丙氨酸羟化酶(PAH)缺乏的代谢紊乱疾病。最近创建的PAH缺乏小鼠品系为探索通过肝脏基因治疗对其进行表型纠正的可能性提供了一个出色的模型系统。构建了一种重组逆转录病毒,其包含在人巨细胞病毒(CMV)启动子转录控制下的小鼠PAH cDNA,并用于转导从PAH缺陷小鼠分离的肝细胞。与对照模拟感染的肝细胞相比,病毒转导的肝细胞产生的小鼠PAH mRNA水平显著更高。PAH mRNA被有效翻译成PAH蛋白,该蛋白能够在体外将苯丙氨酸转化为酪氨酸。这些结果表明,PAH缺陷的小鼠肝细胞可以通过逆转录病毒介导的基因转导轻易地进行重建,这是PKU体细胞基因治疗的关键一步。